by The global Colorectal cancer therapeutics market size was estimated to be around US$ 12.23 billion in 2023. It is projected to reach US$ 18.25 billion by 2032, indicating a CAGR of 4.55% from 2023 to 2032.
Key Takeaways
- North America contributed the highest market share of 38% in 2022.
- Asia-Pacific is estimated to expand the fastest CAGR between 2023 and 2032.
- By therapy, the immunotherapy segment has held the largest market share of 49% in 2022.
- By therapy, the targeted therapy segment is anticipated to grow at a remarkable CAGR of 6.9% between 2023 and 2032.
- By cancer type, the colorectal adenocarcinoma segment has held the largest market share of 47% in 2022.
- By distribution channel, the hospital pharmacies segment has held the largest market share of 45% in 2022.
- By distribution channel, the retail pharmacies segment is anticipated to grow at a remarkable CAGR of 7.4% between 2023 and 2032.
The market research report on the Colorectal cancer therapeutics market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Colorectal cancer therapeutics products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample: https://www.precedenceresearch.com/sample/3643
Colorectal Cancer Therapeutics Market Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 12.23 Billion |
| Market Size by 2032 | USD 18.25 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 4.55% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Therapy, By Cancer Type, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: AI in Life Science Analytics Market will be Worth Nearly $ 5.10 Billion By 2032
The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global Colorectal cancer therapeutics market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Colorectal cancer therapeutics market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Colorectal cancer therapeutics products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the Colorectal cancer therapeutics market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on Colorectal cancer therapeutics market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Colorectal cancer therapeutics market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Recent Developments
- November 2023: U.S. FDA (Food and Drug Administration) announced that it has approved Takeda’s oral targeted therapy for adults with metastatic colorectal cancer (mCRC), FRUZAQLA (fruquintinib). According to the company, FRUZAQLA is a chemotherapy-free treatment option and provide a considerable survival help to patients without much impacting their quality of life.
- August 2023: U.S. Food and Drug Administration (FDA) has approved Taiho Pharmaceutical Co., Ltd. and Taiho Oncology, Inc., LONSURF (trifluridine/tipiracil), to treat adult patients with metastatic colorectal cancer (mCRC) as a single agent or in combination with bevacizumab.
- June 2023: Enzene Biosciences has launched its cheaper drug for treatment of metastatic colorectal cancer, Bevacizumab. It is a biosimilar substitute to the more expensive Avastin.
Colorectal Cancer Therapeutics Market Players
- Bayer AG
- Bristol Myers Squibb
- Eli Lilly and Company
- Genentech, Inc.
- Ipsen Biopharmaceuticals, Inc.
- Merck Sharp & Dohme Corp.
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Taiho Pharmaceutical (Otsuka Pharmaceutical Co., Ltd.)
- Novartis AG
Segments Covered in the Report
By Therapy
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Others
By Cancer Type
- Colorectal Adenocarcinoma
- Gastrointestinal Carcinoid Tumors
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Colorectal Cancer Therapeutics Market
5.1. COVID-19 Landscape: Colorectal Cancer Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Colorectal Cancer Therapeutics Market, By Therapy
8.1. Colorectal Cancer Therapeutics Market, by Therapy, 2023-2032
8.1.1 Targeted Therapy
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Immunotherapy
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Chemotherapy
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Colorectal Cancer Therapeutics Market, By Cancer Type
9.1. Colorectal Cancer Therapeutics Market, by Cancer Type, 2023-2032
9.1.1. Colorectal Adenocarcinoma
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Gastrointestinal Carcinoid Tumors
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Colorectal Cancer Therapeutics Market, By Distribution Channel
10.1. Colorectal Cancer Therapeutics Market, by Distribution Channel, 2023-2032
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Colorectal Cancer Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.1.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.2.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.3.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Therapy (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Cancer Type (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 12. Company Profiles
12.1. Bayer AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol Myers Squibb
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly and Company
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Genentech, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Ipsen Biopharmaceuticals, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Merck Sharp & Dohme Corp.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Regeneron Pharmaceuticals, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sanofi
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Teva Pharmaceutical Industries Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
